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Objectives: Uterine carcinosarcoma is a very aggressive neoplasm. Patients’ median age at 
diagnosis ranges from 62 to 67 years. The aim of this study was to compare treatment results 
and prognostic factors for residents of urban and rural areas suffering from uterine 
carcinosarcoma.  
Material and methods: Clinical outcomes of 58 uterine carcinosarcoma patients treated in one 
institution were assessed: 25 residents of rural and 33 of urban areas. All the patients were 
treated by using surgery followed by chemotherapy (48 pts) or radiotherapy (10 pts). Standard 
2 
 
chemotherapy regimen comprised of paclitaxel 175 mg/m2 and carboplatin on day one at area 
under curve (AUC) six every 21 days. Radiotherapy was performed by combined treatment – 
tele and brachytherapy. External beam pelvic radiation therapy (EBRT) once a day, five days a 
week with a daily fraction size of 1.8 Gy over five weeks at cumulative dose 50.4 Gy was the 
first part of adjuvant treatment. High-dose-rate (HDR) brachytherapy at dose 22.5 Gy was the 
second part of radiotherapy.  
Results: A strong correlation between tumor diameter and the presence of lymph node 
metastasis was observed. Tumor size greater then 4.5 cm correlated with presence of node 
involvement and this parameter was statistically significant (p = 0.015). There was no 
significant correlation between other analyzed clinical factors and overall survival. In the period 
2004 – 2010 43.5% (10/23) and 50% (14/28) of rural and urban residents, respectively, died 
due to carcinosarcoma progression.  
Conclusion: Uterine carcinosarcoma patients in rural and urban areas seem to have similar 
outcomes.   
Key words: carcinosarcoma; rural area; urban area; overall survival; overall survival 
 
INTRODUCTION 
Uterine carcinosarcomas are rare tumors. It represents less than five percent of all 
uterine malignant tumors. In the US, the incidence of carcinosarcoma is approximately 1 to 4 
per 100 000 women [1]. There are no detailed Polish dates about incidence of carcinosarcoma. 
Carcinosarcomas are recognized in women with the median age at diagnosis ranging from 62 
to 67 years. Incidence of uterine carcinosarcoma among blacks is a twofold higher compared 
with non-Hispanic whites [2]. Uterine carcinosarcomas risk factors are similar to endometrial 
carcinomas. Both malignancies are associated with nulliparity, use of exogenous estrogen and 
tamoxifen and obesity [3]. Progestin-containing contraceptives are protective against both types 
of neoplasms. Previous exposure to pelvic radiation can also increase risk of developing uterine 
carcinosarcoma [4]. 
There is no exact information concerning the incidence of uterine carcinosarcoma in 
rural and urban areas. In some South America countries, there are reports presenting distribution 
of gynecological cancers in these two areas [5, 6]. Epidemiology registries have shown that the 
incidence of uterine cancer in rural regions is lower than in urban area. It has been established 
that overall incidence and mortality rates of malignant neoplasms are lower among rural citizen 
in comparison with urban residents [7, 8]. This difference in cancer occurrence may be 
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explained in part to personal health habits such as cigarette and alcohol consumption, 
overweight in urban citizens [8]. Differential distributions of environmental risk factors should 
be also important factors influencing on this epidemiological issue.  
The aim of this study was analysis the survival rates and some prognostic factors of 
uterine carcinosarcoma among residents of rural and urban areas in Poland. 
 
MATERIAL AND METHODS 
Clinical outcomes of 58 uterine carcinosarcoma patients treated at the Maria 
Sklodowska-Curie National Institute of Oncology in Warsaw between 2004 –2011 were 
analyzed. There were 25 rural and urban 33 residents among uterine carcinosarcoma patients.  
Histopathological diagnosis was assessed independently by two pathologists (AN-G and EB-
Z) for all the tumors. The average age of the analyzed group of patients was 62 years (47–78 
range).  
All women were treated by combined methods. After surgery in 48 patients, 
chemotherapy was given and in an additional 10 cases, radiotherapy was performed. In 15 
women a simple hysterectomy with bilateral salpingoophorectomy was performed. In the 
remaining group of patients, radical hysterectomy, pelvic and periaortic lymphadenectomy 
were done. Standard chemotherapy regimen consisted of paclitaxel 175 mg/m2 and carboplatin 
on day one at area under curve (AUC) 6 every 21 days. Most of the patients (46) received six 
cycles of chemotherapy while two women were withdrawn from chemotherapy after four cycles 
because of its toxicity. Ten patients received external beam pelvic radiation therapy (EBRT) 
once a day, five days a week in 26 fractions at cumulative dose 50.4 Gy and high-dose-rate 
(HDR) brachytherapy at dose 22.5 Gy. 
Prognosis analyses were performed taking into consideration the following clinical 
aspects: age, clinical stage, size of the tumor, time from diagnosis to surgery, time of adjuvant 
treatment and lymph node status. All the examined parameters were stratified according the 
rural or urban patients’ residency. No patients were lost and the mean time of follow up was 
247 weeks (149–482 weeks range).  
Statistical analysis was performed using STATISTICA software (StatSoft). Chi2 and 
Pearson test was used for testing sample variance. Log rank test was used for comparing 
survival distributions in the analyzed groups of patients. Kaplan-Meier curves were generated 





        FIGO stage of uterine carcinosarcoma of patients of rural or urban residency is presented 
in Table 1. There were no statistical differences in clinical stage distribution between the two 
groups of patients. Tumor size ranged from 1 to 6 cm (mean 3.5 cm). No difference was 
observed in tumor diameter among rural and urban residents. 
 Mean period from diagnosis to treatment was 4.2 weeks (range 3–7 weeks). Mean time 
of postoperative chemotherapy was 18.6 weeks (range 16–21 weeks). Adjuvant radiotherapy 
lasted on average 6.1 weeks (range 5–7 weeks). There were no statistically significant 
differences in factors mentioned above between either analyzed group.  Eleven out of 23 rural 
residents (44%) and 16 out of 33 women from the urban subgroup (48.5%) died. The mean time 
to progression was 68 and 85 weeks for urban and rural residents, respectively and it was not 
statistically significant. The mean time to death was 149 and 183 weeks for urban and rural 
groups; again, the difference was not statistically significant. Two patients from the rural area 
died due to no oncological reason. One died because of cardiac infarction and the second reason 
was cerebral stroke. Some of the variables in both subgroups of uterine carcinosarcoma patients 
are presented in Table 2. A strong correlation in Pearson test was observed between tumor 
diameter and lymph node involvement. Tumor size greater than 4.5 cm was found to correlate 
with presence of node metastases (p = 0.015). 
Next, we analyzed the correlation between the presence of lymph node metastases and 
uterine carcinosarcoma patients’ overall survival (Fig. 1) Chi2 = 15.015, df = 2 p < 0.015. 
Figure 2 and 3 present Kaplan-Meier curves for progression free survival (log-rank test p = 
0.265) and overall survival (log-rank test p = 0.209) of uterine carcinosarcoma patients, 
respectively, according to their residency.  There was no significant difference in terms of 
survival between the two analyzed groups of patients. 
 
DISCUSSION 
Carcinosarcoma are mixed tumors with both mesenchymal and epithelial components 
of malignant nature. These tumors are considered as one of the most aggressive uterine 
neoplasms. Compared to endometrial carcinoma, carcinosarcoma develops in older age groups. 
Risk factors of these malignancies are similar. Pelvic irradiation, exposure to exogenous 
estrogens or tamoxifen administration are the most common risk factors [8]. 
Differences in survival among rural and urban residents were observed in certain types 
of malignancies [8, 9].  Residents of the rural areas more often have unstaged cancers in 
comparison with urban residents. Among the women with known stages at diagnosis, rural 
residents usually have more advanced disease than urban patients. Taking into consideration 
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the thesis mentioned above, our analysis should show if the same patterns have been observed 
in carcinosarcoma patient’s.  
Our analysis has shown the same clinical characteristics in both groups of residents. 
There were no differences in the clinical stage, time of therapy or the entire treatment duration. 
The incidence of carcinosarcoma was comparable both in rural and urban areas. The similar 
results have been presented in ovarian cancer patients by Szpurek et al. [10]. There are different 
epidemiological data in cases of endometrial and cervical cancer. The Polish National Registry 
has shown less incidents of cervical and endometrial cancers in rural areas than towns and cities. 
We did not observe any discrepancy in staging or diagnostic procedures between rural and 
urban residents. It should be stressed that the time from diagnosis of disease to surgery lasted 
on average 4.2 weeks. This time was comparable in both group of residents. Unfortunately, we 
have no exact data of time duration from beginning of symptoms to diagnosis of malignancy.  
The comparison of progression free survival (PFS) and overall survival (OS) does not allow to 
achieve statistical significance although a tendency of higher values in rural residents was 
observed. This fact may be explained by a healthier environment in rural areas as well as less 
hormonal consumption by rural women [11–14]. 
In most of patients, within the analyzed group, early clinical stages have been diagnosed. 
FIGO stage I and II included 45 out of 58 patients. Medium five-years survival for the total 
population was 53%, which is compatible with other observations. Bosquet et al., analyzed 121 
patients with carcinosarcoma treated with adjuvant chemotherapy following surgery [12]. In 
this study the five-year survival for stage I and II was 59%, for stage III was 22% and for stage 
IV 9%.  
In the analyzed group of patients, chemotherapy and radiotherapy were used as adjuvant 
treatment, but chemotherapy was given to most of the patients. The role of postoperative 
irradiation was assessed in several retrospective series but in only few randomized trials. The 
Gynecologic Oncology Group compared whole abdomen – pelvic irradiation to three cycles of 
chemotherapy based on cisplatin and ifosfamide as adjuvant therapy after surgery, in 206 
eligible patients. The estimated death rate was 29% lower with chemotherapy when compared 
to radiation therapy. This trial has given rise to future clinical trials evaluating adjuvant 
chemotherapy, which has been accepted as standard treatment nowadays [16–18]. The 
combination of carboplatin and paclitaxel replaced doublet regimen mentioned above due to 
less toxicity [19]. It is also our standard regimen which was practiced in analyzed population. 
Radiotherapy was used as adjuvant treatment in the past, but since 2008, this method is 
practiced mostly in recurrences [20].   
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Nodal status appeared to be the most significant prognostic factor in carcinosarcoma. Therefore, 
pelvic and paraaortic lymphadenectomy is mandatory in staging procedures. Regarding its 
impact on survival, the most of studies confirm a significant survival benefit resulting from 
lymphadenectomy [21]. The possible explanation of survival improvement associated with 
lymphadenectomy may include removal of micro-metastatic foci within lymph nodes. The role 
of enlarged lymph nodes removal is no doubt.  Our study also confirms the influence of 




Retrospective analysis made a bias on the final conclusions of this article, but a 
prospective trial would be difficult to conduct in such rare tumors. It should be stressed that 
residents of rural and urban areas have similar prognosis in this type of malignancy. No 
statistically significant differences in overall survival, progression-free survival and 
proportional distribution of clinical stage uterine carcinosarcoma between rural and urban 
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Table 1. Clinical stage in analyzed group 
FIGO Stage Rural residents Urban residents P 




Ib 12 14 
II  5  8 
IIIa  1  0 
IIIb  1  1 
IIIc  3  7 


















Table 2. Analysis of some clinical variable stratified according to site of living 
Variable X2 value P 
Clinical stage 7.421 0.191 
Tumor size 4.447 0.487 
Age 9.125 0.104 
Time to beginning of treatment 8.705 0.069 
Treatment time 10.393 0.238 
Radiotherapy 3.389 0.142 
Chemotherapy 4.075 0.396 
Number of recurrences 1.369 0.241 
















Figure 1. The impact of nodal status on overall survival of carcinosarcoma patients 
 
 
1—lymph node metastasis; 3— without lymph node metastasis; 4—unknown nodal status; 
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